Selective Inhibition of CYP26A1 in the Skin for the Treatment of Ichthyosis

Project: Research project

Project Details

Description

Dr. Paller’s team will further test a new Cyp26 inhibitor compound for comparison with the previously tested compounds, with and without retinoic acid, using 3D models of normal keratinocytes and RXLI/LI subgroups of ichthyosis keratinocytes. This includes growing patient keratinocytes, creating large numbers of normal and ichthyosis 3D cultures, and testing the effect of the compound/ retinoic acid for analysis of RNA and protein expression, as well as histological alteration. The Paller team will also have formal conferences with Dr. Diaz and Dermaxon LLC
StatusActive
Effective start/end date12/1/187/31/21

Funding

  • DermaXon LLC (2R44AR069416-02)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (2R44AR069416-02)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.